Fig. 2

Partial microlgia depletion by low-dose PLX5622 only slightly affects the course of sepsis. A Timeline of experiment: mice were randomized to AIN or low-dose PLX5622 (300 ppm) treatment seven days prior to PCI. After PCI (day 0) all mice received standard AIN chow. B Quantitative analysis of Iba1-positive microglia in the CA1 region of the hippocampus following AIN or PLX5622 treatment at day 0 (n = 3 animals/group; n = 15 images/animal, Student’s t-test). Representative confocal overview and zoom-in images of Iba1-positive microglia in the CA1 region after pretreatment with either AIN or PLX5622 (300 ppm). Scale bar 20 µm and 200 µm. C Kaplan–Meier analysis of PCI induced systemic inflammation following AIN and low-dose PLX5622 between day 0 until day 38 (AIN-sham: n = 20, AIN-PCI: n = 42; PLX5622-sham: n = 20, PLX5622-PCI: n = 45, log-rank test: p < 0.0001). D Clinical severity score (AIN-sham: n = 20, AIN-PCI: n = 42; PLX5622-sham: n = 20, PLX5622-PCI: n = 45; the adapted two-tailed permutation test of Cohen (significance level of 5%) thereby accounting for the multiple-comparison problem has been performed. E Time dynamics in the development of clinical severity score until CSS ≥ 3 (AIN-PCI: n = 42, PLX5622-PCI: n = 45, Mann–Whitney-U-test). F Weight development during pretreatment of AIN or low-dose PLX5622 between day -7 until day 0 and during polymicrobial sepsis between day 0 and day 38 (AIN: sham: n = 20, PCI: n = 42; PLX5622: sham: n = 20, PCI: n = 45; day -7 until day 0: Curve-permutation test (two-tailed), p = 0.3780; day 0 until day 38: Curve-permutation test (two-tailed) with Benjamini–Hochberg correction. Data are presented as mean ± SEM. Individual values are presented as small dots and each circle represents an average of one mouse; individual values and averages are color coded